Lamotrigine high-dose tolerability and safety in patients with epilepsy: A double-blind, placebo-controlled, eleven-week study

Epilepsia

Volumn 37, Issue 9, 1996, Pages 857-862

  Matsuo, Fumisuke ^a,c   Gay, Patricia ^a   Madsen, Jack ^a   Tolman, Keith G ^a   Rollins, Douglas E ^a   Risner, Marcus E ^b   Lai, Allen A ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b GLAXOSMITHKLINE   (United States)

^c UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

Antiepileptic drugs; Clinical trials; Drug evaluation; Epilepsy; Lamotrigine; Pharmacokinetics; Seizures

Indexed keywords

LAMOTRIGINE;

ADULT; ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIPLOPIA; DOSE CALCULATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EPILEPSY; HEADACHE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH;

EID: 0029829941     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1996.tb00038.x     Document Type: Article

References (13)

1. Binnie CD, Debets RMC, Engelsman M, et al. Double-blind crossover trial of lamotrigine (Lamictal®) as add-on therapy in intractable epilepsy. Epilepsy Res 1989;4:222-9.
2. Jawad S, Richens A, Goodwin G, Yuen WC. Controlled trial of lamotrigine (Lamictal®) for refractory partial seizures. Epilepsia 1989;30:356-63.
3. Loiseau P, Yuen AWC, Duché B, et al. A randomized double-blind placebo-controlled crossover add-on trial of lamotrigine in patients with treatment-resistant partial seizures. Epilepsy Res 1990;7:136-45.
4. Sander JWAS, Patsalos PN, Oxley JR, Hamilton MJ, Yuen WC. A randomized double-blind placebo-controlled add-on trial of lamotrigine in patients with severe epilepsy. Epilepsy Res 1990;6:221-6.
5. Matsuo F, Bergen D, Faught E, et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. Neurology 1993;43:2284-91.
6. Messenheimer J. Ramsay RE, Willmore LJ, et al. Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, crossover trial. Epilepsia 1994;35:113-21.
7. Schachter S, Leppik I, Matsuo F, et al. Lamotrigine: a six-month, placebo-controlled, safety and tolerance study. J Epilepsy 1995;8:201-9.
8. Cohen AF, Land GS, Breimer DD, et al. Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin Pharmacol Ther 1987;42:535-41.
9. Hubbell JP, Garnett WR, Pellock JM, et al. Pharmacokinetics of lamotrigine (BW430C) in epileptic patients. Epilepsia 1985;26:537.
10. Jawad S, Yuen WC, Peck AW, et al. Lamotrigine: single-dose pharmacokinetics and initial 1 week experience in refractory epilepsy. Epilepsy Res 1987;1:194-201.
11. Lai A, Wargin WA, Garnett WR, et al. Pharmacokinetics of lamotrigine in epileptic patients following multiple oral dosing. Epilepsia 1986;27:647-8.
12. Ramsay RE, Pellock JM, Garnett WR, et al. Pharmacokinetics and safety of lamotrigine (Lamictal®) in patients with epilepsy. Epilepsy Res 1991;10:191-200.
13. Doig M, Clare R. Use of thermospray liquid chromatography-mass spectrometry to aid in the identification of urinary metabolites of a novel antiepileptic drug, lamotrigine. J Chromatogr 1991;554:181-9.